scholarly journals miR-7111-5p and miR6870-5p may be Potential Biomarkers for Oral Squamous Cell Carcinoma

Author(s):  
mona saraei
Author(s):  
Paola Fernandes Pansini ◽  
Isabella Bittencourt do Valle ◽  
Thabata Coeli Dias Damasceno ◽  
Priscila Marinho de Abreu ◽  
Anna Clara Gregório Có ◽  
...  

Head & Neck ◽  
2021 ◽  
Author(s):  
Mark Jakob ◽  
Lena M. Mattes ◽  
Kristian Unger ◽  
Stefan Kueffer ◽  
Julia Hess ◽  
...  

2018 ◽  
Vol 47 (1) ◽  
pp. 26-38 ◽  
Author(s):  
Tingru Shao ◽  
Jiaxin Huang ◽  
Zenan Zheng ◽  
Qingqing Wu ◽  
Tiancai Liu ◽  
...  

Background/Aims: Oral squamous cell carcinoma (OSCC) is one of the most lethal malignancies worldwide and the most common type of oral cancer, characterized by invasive growth, frequent regional metastases, high recurrence, and poor prognosis. In the current study, we investigated the use of long non-coding RNAs (lncRNAs), tumor-specific growth factor (TSGF), and squamous cell carcinoma antigen (SCCA) as potential biomarkers for OSCC screening. Methods: LncRNA expression was measured by microarray analysis in three sets of OSCC and paired normal mucosal tissues. The potential lncRNAs involved in OSCC development were investigated by bioinformatics and verification experiments. We also determined the expression of these potential biomarkers in tissue and serum samples in a case–control study of 80 OSCC cases and 70 controls. Receiver operating characteristics, decision curve analysis, and the combined detection of lncRNA AC007271.3, TSGF, and SCCA were carried out to screen for OSCC biomarkers. Results: A total of 691 lncRNAs (433 upregulated and 258 downregulated) were differentially expressed in OSCC tissues compared with normal controls (p< 0.05). Based on Gene Ontology and pathway analysis, we selected four differentially expressed lncRNAs (AC007271.3, AC007182.6, LOC283481, and RP11-893F2.9), and showed that aberrant AC007271.3 levels in OSCC patients were significantly associated with clinical stage, especially in early-stage disease, in an expanded case–control study. The combination of AC007271.3 and SCCA (AUC=0.902, p< 0.001) showed significantly better ability to discriminate between OSCC and controls compared with SCCA or AC007271.3 alone. Serum AC007271.3, SCCA, and TSGF levels could also discriminate between OSCC and normal controls with sensitivities of 77.6%, 55.0%, and 63.3%, and specificities of 84.5%, 93.3%, and 66.7%, respectively. Conclusions: These results suggest that AC007271.3, SCCA, and TSGF could be novel circulating biomarkers for the determination of OSCC. However, further validation in large-scale prospective studies is necessary.


2010 ◽  
Vol 5 (2) ◽  
pp. 60-69 ◽  
Author(s):  
Wei-Chung Vivian Yang ◽  
Ho-Ren Chung ◽  
Jia-Yo Wu ◽  
Chen Yi ◽  
Duen-Jeng Wang ◽  
...  

2021 ◽  
Vol 10 (1) ◽  
pp. 141-151
Author(s):  
Zhijun Zhang ◽  
Fei Bi ◽  
Zhuang Zhang ◽  
Weidong Tian ◽  
Weihua Guo

2021 ◽  
Vol 11 ◽  
Author(s):  
Mingfei Wang ◽  
Linfeng Zhang ◽  
Wenhao Ren ◽  
Shaoming Li ◽  
Keqian Zhi ◽  
...  

IntroductionCircular RNAs (CircRNAs), an emerging non-coding RNA, have been demonstrated to be involved in tumorigenesis, metastasis, and cancer progression, and could represent novel potential biomarkers for diagnosing oral squamous cell carcinoma (OSCC). However, no meta-analysis has investigated the diagnostic role of circRNAs in OSCC. Hence, to investigate whether circRNAs could serve as specific biomarkers for OSCC, the present systematic review and meta-analysis evaluated the diagnostic efficiency of circRNAs in patients with OSCC.Materials and MethodsA thorough search of online databases (Pubmed, Web of Science, Embase, and the Cochrane Library) was conducted to collect relevant studies up to March 30th, 2021. All eligible studies were case-control studies. The quality of each study was evaluated by the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. STATA (version 15.1) and Review Manager (version 5.4) were employed to conduct the meta-analysis, and the PRISMA statement was adopted in this study.ResultsA total of 16 studies were included in the meta-analysis, with five studies on upregulated circRNAs, and 11 on downregulated circRNAs. The enrolled studies that met our eligibility criteria all derived from China. The pooled sensitivity (SEN), specificity (SPE), diagnostic odds ratio (DOR), positive likelihood ratio (PLR), negative likelihood ratio (NLR), and the area under receiver operating characteristics curve (AUC) with the 95% confidence intervals (95% CIs) were 0.74 (0.69–0.79), 0.79 (0.73–0.84), 10.74 (7.81–14.77), 3.50 (2.78–4.45), 0.33 (0.27–0.39) and 0.83 (0.79–0.86), respectively. The subgroup analysis demonstrated that serum, plasma, and saliva specimens had a better diagnostic performance than tissue samples, with a high value of sensitivity, specificity, DOR, and AUC values. The results also showed that the subgroups of upregulated circRNAs and a sample size of ≥100 manifested higher specificity, DOR, and AUC for cancer detection than downregulated circRNAs and a sample size of &lt; 100.ConclusionsA strong association was demonstrated between the dysregulated expression of circRNAs and the diagnosis of OSCC. Hence, circRNAs have the potential to function as promising biomarkers and therapeutic targets for OSCC.Systematic Review RegistrationPROSPERO, number CRD42021256857.


Sign in / Sign up

Export Citation Format

Share Document